open access
Vemurafenib and concomitant stereotactic radiation for the treatment of melanoma with spinal metastases: A case report
open access
Abstract
A 56-year-old man with BRAFV600E melanoma and spinal metastases treated with vemurafenib and stereotactic radiation showed a partial response without neurological, skin or mucosal toxicity, 8 months after completion of this combination. This case suggests that stereotactic radiation spares normal tissues and might be safer than conventional fractionated radiation with vemurafenib.
Abstract
A 56-year-old man with BRAFV600E melanoma and spinal metastases treated with vemurafenib and stereotactic radiation showed a partial response without neurological, skin or mucosal toxicity, 8 months after completion of this combination. This case suggests that stereotactic radiation spares normal tissues and might be safer than conventional fractionated radiation with vemurafenib.
Keywords
Vemurafenib; Stereotactic radiation; Melanoma metastasis
About this articleTitle
Vemurafenib and concomitant stereotactic radiation for the treatment of melanoma with spinal metastases: A case report
Journal
Reports of Practical Oncology and Radiotherapy
Issue
Pages
76-80
Published online
2016-01-01
DOI
10.1016/j.rpor.2015.07.005
Bibliographic record
Rep Pract Oncol Radiother 2016;21(1):76-80.
Keywords
Vemurafenib
Stereotactic radiation
Melanoma metastasis
Authors
Dinu Stefan
Hosni Popotte
Andreea Raluca Stefan
Audrey Tesniere
Aurélie Tomaszewski
Paul Lesueur
Jean-Louis Habrand
Laurence Verneuil